Virpax Pharmaceuticals, Inc.
Virpax Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing innovative, non-addictive pain management solutions and treatments for central nervous system disorders. The company leverages proprietary drug delivery technologies to optimize patient care and address unmet medical needs in various therapeutic areas, including postoperative pain, severe pain, and rare pediatric epilepsy. As a preclinical-stage pharmaceutical company, Virpax is dedicated to enhancing compliance and optimizing its product candidates through novel drug delivery systems.
Virpax Pharmaceuticals, Inc.
1055 Westlakes Drive, Suite 300, Berwyn, PA 19312
What We Do
Drug Development
Virpax specializes in developing non-addictive pharmaceutical products for pain management and CNS disorders, utilizing advanced drug delivery technologies.
Research Collaborations
The company collaborates with prestigious institutions like the National Institutes of Health and the U.S. Army Institute of Surgical Research to advance its product candidates.
An injectable long-acting liposomal bupivacaine formulation designed for postoperative pain management, providing pain relief for up to 96 hours.
An intranasal enkephalin formulation aimed at managing acute and chronic pain, including cancer-related pain, without the side effects associated with opioids.
An intranasal pharmaceutical-grade cannabidiol (CBD) product being developed for the management of rare pediatric epilepsy.
Battlefield Resuscitation
Services
FDA Regulated Medical Devices
Drugs
Application Area
News & Updates
Virpax announced results from a minipig Dose Range Finding study for Probudur, demonstrating positive tolerance and no adverse effects.
Virpax has been granted an extension of its cooperative research and development agreement with NCATS for the continued development of NES100.